INARI MEDICAL INC (NARI) Fundamental Analysis & Valuation

NASDAQ:NARI • US45332Y1091

Current stock price

79.97 USD
+0.04 (+0.05%)
At close:
79.98 USD
+0.01 (+0.01%)
After Hours:

This NARI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. NARI Profitability Analysis

1.1 Basic Checks

  • In the past year NARI has reported negative net income.
  • In the past year NARI had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: NARI reported negative net income in multiple years.
  • In multiple years NARI reported negative operating cash flow during the last 5 years.
NARI Yearly Net Income VS EBIT VS OCF VS FCFNARI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 0 20M -20M

1.2 Ratios

  • NARI has a Return On Assets (-11.27%) which is comparable to the rest of the industry.
  • NARI has a Return On Equity of -18.07%. This is in the better half of the industry: NARI outperforms 60.96% of its industry peers.
Industry RankSector Rank
ROA -11.27%
ROE -18.07%
ROIC N/A
ROA(3y)-0.97%
ROA(5y)0.17%
ROE(3y)-1.09%
ROE(5y)-0.88%
ROIC(3y)N/A
ROIC(5y)N/A
NARI Yearly ROA, ROE, ROICNARI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 -20 -40 -60

1.3 Margins

  • Looking at the Gross Margin, with a value of 86.82%, NARI belongs to the top of the industry, outperforming 97.33% of the companies in the same industry.
  • NARI's Gross Margin has improved in the last couple of years.
  • NARI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 86.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.99%
GM growth 5Y1.71%
NARI Yearly Profit, Operating, Gross MarginsNARI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. NARI Health Analysis

2.1 Basic Checks

  • NARI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • NARI has more shares outstanding than it did 1 year ago.
  • NARI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NARI Yearly Shares OutstandingNARI Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
NARI Yearly Total Debt VS Total AssetsNARI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

  • NARI has an Altman-Z score of 11.25. This indicates that NARI is financially healthy and has little risk of bankruptcy at the moment.
  • NARI has a better Altman-Z score (11.25) than 90.91% of its industry peers.
  • There is no outstanding debt for NARI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 11.25
ROIC/WACCN/A
WACC8.93%
NARI Yearly LT Debt VS Equity VS FCFNARI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 100M 200M 300M 400M

2.3 Liquidity

  • NARI has a Current Ratio of 1.77. This is a normal value and indicates that NARI is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Current ratio value of 1.77, NARI is not doing good in the industry: 71.12% of the companies in the same industry are doing better.
  • NARI has a Quick Ratio of 1.40. This is a normal value and indicates that NARI is financially healthy and should not expect problems in meeting its short term obligations.
  • The Quick ratio of NARI (1.40) is worse than 64.17% of its industry peers.
Industry RankSector Rank
Current Ratio 1.77
Quick Ratio 1.4
NARI Yearly Current Assets VS Current LiabilitesNARI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. NARI Growth Analysis

3.1 Past

  • The earnings per share for NARI have decreased strongly by -1183.33% in the last year.
  • Looking at the last year, NARI shows a very strong growth in Revenue. The Revenue has grown by 22.39%.
  • NARI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 135.60% yearly.
EPS 1Y (TTM)-1183.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-280%
Revenue 1Y (TTM)22.39%
Revenue growth 3Y52.31%
Revenue growth 5Y135.6%
Sales Q2Q%21.39%

3.2 Future

  • NARI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 121.24% yearly.
  • The Revenue is expected to grow by 17.44% on average over the next years. This is quite good.
EPS Next Y-2492.94%
EPS Next 2Y192.8%
EPS Next 3Y191.18%
EPS Next 5Y121.24%
Revenue Next Year22.24%
Revenue Next 2Y20.1%
Revenue Next 3Y18.92%
Revenue Next 5Y17.44%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
NARI Yearly Revenue VS EstimatesNARI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
NARI Yearly EPS VS EstimatesNARI Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 1 2

More info and screens

Find the best growth stocksShow best growing peers

2

4. NARI Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for NARI. In the last year negative earnings were reported.
  • NARI is valuated quite expensively with a Price/Forward Earnings ratio of 405.53.
  • Based on the Price/Forward Earnings ratio, NARI is valued a bit cheaper than 64.71% of the companies in the same industry.
  • NARI's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 23.13.
Industry RankSector Rank
PE N/A
Fwd PE 405.53
NARI Price Earnings VS Forward Price EarningsNARI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 100 -100 200 300 400

4.2 Price Multiples

  • Based on the Price/Free Cash Flow ratio, NARI is valued a bit cheaper than the industry average as 66.84% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 2971.47
EV/EBITDA N/A
NARI Per share dataNARI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

  • A more expensive valuation may be justified as NARI's earnings are expected to grow with 191.18% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y192.8%
EPS Next 3Y191.18%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NARI Dividend Analysis

5.1 Amount

  • No dividends for NARI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

NARI Fundamentals: All Metrics, Ratios and Statistics

INARI MEDICAL INC

NASDAQ:NARI (2/18/2025, 8:00:58 PM)

After market: 79.98 +0.01 (+0.01%)

79.97

+0.04 (+0.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-28
Earnings (Next)03-04
Inst Owners95.33%
Inst Owner Change0%
Ins Owners3.81%
Ins Owner Change0%
Market Cap4.68B
Revenue(TTM)574.50M
Net Income(TTM)-78.58M
Analysts77.27
Price Target76.99 (-3.73%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-61.42%
Min EPS beat(2)-154%
Max EPS beat(2)31.16%
EPS beat(4)1
Avg EPS beat(4)-384.45%
Min EPS beat(4)-1407.19%
Max EPS beat(4)31.16%
EPS beat(8)5
Avg EPS beat(8)-35.38%
EPS beat(12)8
Avg EPS beat(12)-18.85%
EPS beat(16)11
Avg EPS beat(16)50.45%
Revenue beat(2)0
Avg Revenue beat(2)-0.37%
Min Revenue beat(2)-0.55%
Max Revenue beat(2)-0.19%
Revenue beat(4)1
Avg Revenue beat(4)-0.25%
Min Revenue beat(4)-1.73%
Max Revenue beat(4)1.46%
Revenue beat(8)5
Avg Revenue beat(8)0.59%
Revenue beat(12)9
Avg Revenue beat(12)1.56%
Revenue beat(16)13
Avg Revenue beat(16)3.41%
PT rev (1m)12.89%
PT rev (3m)17.02%
EPS NQ rev (1m)250.29%
EPS NQ rev (3m)250.29%
EPS NY rev (1m)-2.57%
EPS NY rev (3m)-2.25%
Revenue NQ rev (1m)-0.01%
Revenue NQ rev (3m)0.07%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.02%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 405.53
P/S 8.15
P/FCF 2971.47
P/OCF 330.4
P/B 10.77
P/tB 60.34
EV/EBITDA N/A
EPS(TTM)-0.77
EYN/A
EPS(NY)0.2
Fwd EY0.25%
FCF(TTM)0.03
FCFY0.03%
OCF(TTM)0.24
OCFY0.3%
SpS9.81
BVpS7.42
TBVpS1.33
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -11.27%
ROE -18.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 86.82%
FCFM 0.27%
ROA(3y)-0.97%
ROA(5y)0.17%
ROE(3y)-1.09%
ROE(5y)-0.88%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.99%
GM growth 5Y1.71%
F-Score3
Asset Turnover0.82
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 86.41%
Cap/Sales 2.19%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.77
Quick Ratio 1.4
Altman-Z 11.25
F-Score3
WACC8.93%
ROIC/WACCN/A
Cap/Depr(3y)251.19%
Cap/Depr(5y)332.22%
Cap/Sales(3y)2.93%
Cap/Sales(5y)3.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1183.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-280%
EPS Next Y-2492.94%
EPS Next 2Y192.8%
EPS Next 3Y191.18%
EPS Next 5Y121.24%
Revenue 1Y (TTM)22.39%
Revenue growth 3Y52.31%
Revenue growth 5Y135.6%
Sales Q2Q%21.39%
Revenue Next Year22.24%
Revenue Next 2Y20.1%
Revenue Next 3Y18.92%
Revenue Next 5Y17.44%
EBIT growth 1Y-352.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-278.61%
EBIT Next 3Y107.8%
EBIT Next 5YN/A
FCF growth 1Y107.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y238.69%
OCF growth 3Y165.95%
OCF growth 5YN/A

INARI MEDICAL INC / NARI Fundamental Analysis FAQ

What is the fundamental rating for NARI stock?

ChartMill assigns a fundamental rating of 4 / 10 to NARI.


What is the valuation status for NARI stock?

ChartMill assigns a valuation rating of 2 / 10 to INARI MEDICAL INC (NARI). This can be considered as Overvalued.


How profitable is INARI MEDICAL INC (NARI) stock?

INARI MEDICAL INC (NARI) has a profitability rating of 3 / 10.


What is the financial health of INARI MEDICAL INC (NARI) stock?

The financial health rating of INARI MEDICAL INC (NARI) is 6 / 10.